One giant LEAP for regenerative medicine
12 January, 2018Exopharm has finalised testing for its disruptive LEAP technology, taking a further step in bringing extracellular vesicles as an acellular therapy to treat patients with degenerative conditions.
Cancer-fighting seaweed
11 December, 2017Animal studies undertaken at UTHealth have shown that the two seaweed extracts — known as fucoidans — have reduced tumour growth in select cancers and significantly improved the effectiveness of the common chemotherapy drug tamoxifen.
Cannabis-based epilepsy drug coming in 2018
07 December, 2017MGC Pharmaceuticals has executed a binding definitive exclusive supply agreement with pharmaceutical wholesaler HL Pharma to bring its adult epilepsy product, CannEpil, to the Australian market in 2018.
Bio-Gene Technology collaborates with CSIRO on insecticide development
01 December, 2017Bio-Gene Technology, a manufacturer of insecticides, has entered into an extended research agreement with CSIRO to develop improved manufacturing systems for its lead product, Flavocide.
Strong anticancer activity identified in newly patented AAD compounds
29 November, 2017PharmAust has been granted a new patent in the US covering its portfolio of anticancer drugs, recently proven to be more effective at killing cancer cells than their parent compound.
Lonza XS Pichia 2.0 Expression and Manufacturing Platform
24 November, 2017Lonza has developed an expression and manufacturing system that provides high product titres (up to 6 g/L) along with a fast, robust and scalable manufacturing process suitable for commercial production. The XS Pichia 2.0 system is said to deliver high cell viability for improved product quality; reduced fermentation times that approximate E. coli processes; and ease of implementation in large-scale plants.
Biotron compounds demonstrate antiviral activity against hep B
17 November, 2017Biotron has announced that several of its compounds have demonstrated significant antiviral activity against hepatitis B (HBV) in recently completed preclinical studies.
Prima BioMed announces positive data, pre-IND meeting for anticancer candidate
16 November, 2017Prima BioMed has presented new data from a phase I clinical trial investigating eftilagimod alpha, its anticancer candidate, in combination with pembrolizumab in unresectable or metastatic melanoma patients.
Shining a light on small diseased tissues
13 November, 2017Singaporean researchers have created polymer nanoagents that can 'light up' tiny areas of diseased tissues that conventional methods fail to detect.
New ARC training centre dedicated to biopharmaceuticals
09 November, 2017The ARC Industrial Transformation Training Centre in Biopharmaceutical Innovation has been officially opened at The University of Queensland, 16 months after it was initially announced.
Researchers discover a missing piece of the drug design jigsaw
10 October, 2017UK researchers have discovered a new way of analysing how drugs interact with molecules in the body, which could lead to the development of better treatments with fewer side effects.
MTPConnect signs MoU with Medical Alley Association
05 October, 2017MTPConnect has signed a memorandum of understanding with the Medical Alley Association, a Minnesota-based organisation that enables health innovation and care organisations to successfully influence the evolution of health care.
Printed medication: the future of pharmaceuticals
03 October, 2017US scientists have developed technology that can print pure, ultraprecise doses of drugs onto a wide variety of surfaces, in a breakthrough that could one day enable on-site printing of custom-dosed medications at pharmacies, hospitals and other locations.
Diabetes drug found to have anti-ageing properties
18 September, 2017Australian researchers have discovered that metformin, a common anti-diabetic drug, could have anti-ageing properties which could lead to longer, healthier lifespans.
BioScience Managers invests in REX Bionics
12 September, 2017Australian life sciences investment firm BioScience Managers has chosen a robotic exercise assist device (REX) as its first investment for the Biomedical Translation Fund.
